First-line treatment for hypertension

American Family Physician

Volumn 81, Issue 11, 2010, Pages 1333-1335

  Bui, Quynh ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; PLACEBO; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; MORBIDITY; MORTALITY; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; TREATMENT DURATION; ARTICLE; FEMALE; MIDDLE AGED;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 77953713806     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009;(3):CD001841.
2. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;(1):CD002003.
3. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(8):936-946.
4. Wright JT Jr, Probstfield JL, Cushman WC, et al.; ALLHAT Collaborative Research Group. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169(9):832-842.
5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2004;291(18):2196, and JAMA. 2003;289(2):178]. JAMA. 2002;288(23):2981-2997.
6. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356(9227):359-365.